.-: , 1998.-.64-66.
6. : -
/.., ..,
.., ..// .-2001.-10.-.25-32.
7. - /..,.. , .. .//. . . .-1999.-.4.-.12-16.
8. -
/.., .., .-, ..// .-2002.-2.-.28-32.
9. .. //. .-2001 .-3.-.5-9.
10. .., .., .. , //. .-2003.-3.-.73-75.
11. Bateman E.D., Bousquet J., Braunstein G.L. Is overall asthma control being achieved? A hypothesis-generating study//Eur. Respir. J.-2001.-Vol.17.-P.589-595.
12. Mechanisms of glucocorticoid-resistant asthma/D.Y.Leung, M. de Castro, S.J. Szefler, G.P.Chrousos//Ann. N.Y. Acad. Sci.-1998.-Vol.840.-P.735-746.

616.248+616.233-002-036.12]-073.7:611.778:681.3
.., .., .., ..


SUMMARY
: () () () (), (). 183 : 43 , 110 1-1 30 . : , . . - - (200 ) - (4 ). , . - .
G.I.Sukhanova, L.I.Ivanova, V.A.Petrakovskaya, M.Ph.Kinaikin
COMPUTER DERMOGRAPHY METHOD USED IN BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE DIAGNOSTICS
The purpose of this study was to assess a significance of computed dermography (CD) method for detecting latent bronchoobstruction (BO) in patients with bronchial asthma (BA) during clinical remission and the actual degree of severity of bronchoobstructive syndrome (BOS), latent reversible obstruction in patients with chronic obstructive pulmonary disease (COPD). 183 persons were examined: 43 patients with intermittent and mild BA during clinical remission, 110 patients with COPD at the I-IVth stages during exacerbation period and 30 healthy persons. The bronchial patency was diagnosed by instrumental methods: CD, spirography, peak flowme-try. The physical exertion test has been done to detect latent BO in BA patients. We performed the pharmacologic test with salbutamol (200 mkg) in BA patients and with berodual (4 doses) in COPD patients so as to assess BO reversibility. The CD method was found to be more sensitive compared with spirography and peak flowmetry,
which allowed detecting latent BO and bronchial hyperreactivity in patients with intermittent and mild BA during clinical remission. Diagnostic CD-criteria of BOS severity in patients with COPD have been determined.
() () , [2, 3, 7, 8].
- () , , , [1, 4]. [1, 4, 9]. -, , , . - [4]. (), , , , , [1]. , . , 10% , [9]. , . , , [1]. . ї (brittle) [1]. , . , , . , [7].
,
, . (), - (.. 1531993 01.09.1989 . ї, . ., .., . .) ( 195/23-560-91 14.06.91 .; 142 30.06.94) [5, 6].
- , - . , , , . - , , .
: ; ; 3- ; ; ; ; ; , , .
: () , .

43 - (19 24 ) 16 - 31 (18 - , 25 - ) ( 1 5 ). 110 (92 18 ) 38 70 (19 - I (), 38 - II (), 53 - III IV ( ) 30 20-23 , . ,
[2]. [8]. , , , , .
, ( 88-500, , ) -, (%) ( ї, ) (/), 15 30 . , 1,5-2 . , . , , , , . . . , , . . (200 ) (4 ). -01ї -01-03. - 8-08 8.
-01 ( - - ) , . 183 1 , 5 , , , .
. , . 6 : - , - , - , 8 -
- , - *. . , , , . , : 1 - , 2 - , 3 - , 4 - , 5 - - . - .

1 , - . ^8 -2 . 1 2- . - 2- , 2- (, ). - . (. 1) - 1 : - - 0,75±0,04 . . 0,3-1 . ., - 0,53±0,067 . . 0,1-1,5 . . :-8, -2.
- 1 ( ) 1-8 -, - 1 (>1 . .), ї -, , - 1.
43 - (1), (). - .
, 7 (38,9%) 18
6 (24%) 25 ( - 1, , 1,52±0,19 . . 1,64±0,06 . ., <0,05), (0,75±0,04 . .), - (200 ), , . . . , 1 ( -97,75±0,49%, - 96,63±0,68%) ( - 98,93±0,32%, - 98,60±0,26%) (>0,05).
2, 1 ., 21
, , . 0 ., . : 1) - -; 2) ї -, 4 ; 3) - - 1,2 . ., .. ( - 0,75±0,04 . .). , , 1 .
, (1) () ( 7 11 ), ( 6 10 ), - - 1 -
. 1. 1 . - - , - - .
. 2. 1 ., 21 , - , . 0 . 1 - 115%. - 99%.
. 3. F1 ., 21 , - , . 0 . 1 - 89%. - 83%.
( - 1,76±0,12 . . - 0,71±0,05 . .). 1 ( - 83,43±0,39% -
84,16±0,42%) ( - 83,18±0,41% - 88,11±0,14%) 15% ( - - 4, - 3 ). .
3, F1 ., 21 , , . 0 . - 2,1 . . .
7 - 6 , . , 4 7 3 6 , . 1 6 .
, , , 7 6 - , - 4 3 - , .
-
(200 , ). , .
4, ., 21 , , . 0 .
2 , 2 - , . 1 , - .
. , , , . - : (=5), (=2), (=6), , (2 .), 3-4 (=2), - (=2), (=2). .
. 4. F1 ., 21 , - , . 0 . ! - 111%. - 102%.
1
- 1


-
- . . 1,1 1,5 1,6 3 3,1 7,5
- - . . 0,4 1,5 1,6 3 3,1 5,5
ї
, ї 3 4 3 6 5 11
, 6 3 - 20,4±1,31% ( 10% ). . , , . . .
, .
. , , , .
( ) -
- , (. 1).
, (1) () , 110 (. 2).
I (79 ) , , . . .
II (7 ) , , . . 1, . , II , - . , , , .
, III IV . -
2
1 (1), () (±)
I , =79 II , =7 III , =24
- 1, . . 3,63±0,20 5,79±0,68 2,29±0,12
3,04±0,18* 5,76±0,68 1,93±0,12*
- - 1, . . 2,69±0,16 4,47±0,37 1,73±0,15
2,29±0,15* 4,31±0,39 1,33±0,15*
5,53±0,27 7,86±1,21 4,29±0,27
4,53±0,19** 7,43±0,99 3,38±0,14**
% 47,23±2,0 30,29±3,16 41,75±1,38
55,0±2,13** 30,14±3,47 43,50±1,47
, % 48,39±1,77 33,86±2,30 42,67±1,40
56,89±1,88** 35,86±2,39 44,50±1,25
: * - ( ) <0,05;
** - ( ) <0,01.
. , - ( <40%). , .
1, . , III (24 ) , .
III , 1 . - 50-100 , , . ( , ), ( ). - , 1 , .. 1, - . - 1 , , , . . . , , , . , , , , 1 -
. 1 , . , .
1, . , , 1 . 1 - , .
, . , , . .

1. , .
2. .
3. .

1. .., .. - -//. . .-1997.-1.-.30-33.
2.
/ . ...-.: , 2002.-160 .
3. .. //-.-2001.-1.-.105-118.
4. .., .., -
.. - //
: . . ./. . .., ...-., 1987.-.71-89.
5. . 8900053, 8/8, -/.., .., ..,
..//. .-1989.
6. : .. 1531993, / .. , .., .., ..-//. .-1989.-48.-.37.
7. .. .-.: , 2001.-144 .
8. Global Initiative for Chronic Obstructive Lung disease. Global Strategy for Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Workshop Report Publication 2701, 2003.
9. Miller M. R., Pedersen O. F. Peakflow meter resistance decreases peak expiratory flow in subjects with COPD//J. Appl. Physiol.-2000.-Vol.89, 1.-P.283-290.

616.248-08:612.017
.., .., ..




98 - .
SUMMARY
Yu.S.Landyshev, A.Yu.Basilevich, T.N.Chaplenko
RHEOPULMONOGRAPHY ROLE IN EVALUATION BASIC THERAPY
EFFECTIVENESS IN BRONCHIAL ASTHMA
The paper describes the results of a complex investigation aimed at studying inhaled glukocor-ticosteroid effectiveness in 98 patients combined with clinical examination including zone ventilation and lung circulation study.
, (), 23-60% [3]. , . () , [4, 9, 10, 13]. -
[4, 6, 12]. , [1, 4, 8].
.
: ; , , , - .

98 18 60 , 6±2,4 . 57,1% , 42,9% . 36 , 43 19 .
-, . I - 44 , ! 18 -